Evidence-Based Interventional Oncology for Liver Cancer in Shanghai
Effective liver cancer treatment increasingly depends on combining multiple interventional modalities — ablation, arterial chemoembolization, and hepatic arterial infusion — in individualized sequences guided by the latest translational research. At Renji Hospital's Department of Interventional Oncology, Dr. Shi Yaoping brings both deep clinical expertise and a strong research foundation to the comprehensive interventional management of hepatocellular carcinoma.
Featured Specialist: Dr. Shi Yaoping (史瑶平)
Dr. Shi Yaoping is Associate Chief Physician and Deputy Director of the Department of Interventional Oncology at Renji Hospital, Shanghai Jiao Tong University School of Medicine (Shanghai Jiaotong Daxue Yixueyuan Fushu Renji Yiyuan). She works within one of China's highest-volume interventional oncology programs, alongside Chief Physician Dr. Xu Aimin.
Dr. Shi's clinical profile combines:
- Comprehensive interventional treatment of liver cancer — ablation (RFA, MWA), transarterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC)
- Translational research expertise — a strong foundation in basic and clinical translational research on comprehensive liver cancer treatment, bridging laboratory findings to clinical protocols
- Individualized treatment planning — selecting and sequencing interventional modalities based on tumor characteristics, liver function, and the latest evidence
Comprehensive Interventional Treatment: The Multi-Modality Approach
Modern interventional oncology for liver cancer is not a single procedure — it is a carefully orchestrated combination of techniques, each addressing different aspects of the tumor and its biology. Dr. Shi's comprehensive approach integrates:
Thermal Ablation: Radiofrequency Ablation (RFA) and Microwave Ablation (MWA)
- A needle electrode or antenna is inserted directly into the tumor under CT or ultrasound guidance
- Thermal energy destroys tumor cells through heat, achieving complete tumor necrosis
- RFA: Established technique with extensive long-term outcome data; ideal for tumors ≤3 cm
- MWA: Faster heating, larger ablation zones, less susceptible to heat-sink effect from adjacent blood vessels; increasingly preferred for tumors 3–5 cm and perivascular locations
- For small HCC (≤3 cm), ablation achieves outcomes comparable to surgical resection with significantly lower morbidity
- Can be performed percutaneously (through the skin), laparoscopically, or intraoperatively
Transarterial Chemoembolization (TACE)
- Catheter-directed delivery of chemotherapy and embolic agents into the hepatic artery supplying the tumor
- Standard of care for intermediate-stage HCC (BCLC-B) — tumors too large or numerous for ablation, but without extrahepatic spread
- Conventional TACE (cTACE): Lipiodol-based chemotherapy emulsion followed by gelatin sponge embolization
- Drug-eluting bead TACE (DEB-TACE): Microspheres loaded with doxorubicin for sustained drug release and reduced systemic toxicity
- Response assessment by modified RECIST (mRECIST) criteria — evaluating viable tumor enhancement rather than size alone
Hepatic Arterial Infusion Chemotherapy (HAIC)
- Continuous infusion of high-dose FOLFOX chemotherapy (oxaliplatin + fluorouracil + leucovorin) directly into the hepatic artery via an implanted port
- Achieves intratumoral drug concentrations 10–50 times higher than systemic chemotherapy
- Particularly effective for advanced HCC with portal vein tumor thrombus (PVTT) — a situation where TACE is often contraindicated and systemic therapy has limited efficacy
- Increasingly combined with systemic targeted therapy (lenvatinib, sorafenib) and immunotherapy (PD-1 inhibitors) for synergistic effect
- Can achieve tumor downstaging to enable subsequent surgery or transplantation in selected patients
Combination and Sequential Strategies
- TACE + ablation: TACE first to reduce vascularity and heat-sink effect, followed by ablation for more complete tumor destruction — effective for tumors 3–5 cm
- HAIC + targeted therapy + immunotherapy: Triple combination for advanced HCC, with emerging evidence of high response rates and downstaging potential
- Ablation + systemic therapy: Ablation of the primary tumor combined with systemic therapy for micrometastatic disease control
Translational Research: From Bench to Bedside
Dr. Shi's research background in basic and clinical translational research on liver cancer treatment means that her patients benefit from protocols informed by the latest scientific understanding of:
- Tumor microenvironment changes after ablation and TACE — and how these can be exploited to enhance immunotherapy response
- Biomarkers predicting response to TACE and ablation
- Mechanisms of resistance to locoregional therapy and strategies to overcome them
- Optimal sequencing of interventional and systemic therapies based on tumor biology
Who Should Consider Consulting Dr. Shi?
- Patients with early HCC (≤5 cm) who are not surgical candidates and need ablation
- Patients with intermediate HCC (multiple tumors, larger size) requiring TACE
- Patients with advanced HCC with portal vein involvement who need HAIC-based combination therapy
- Patients who have had incomplete response to previous TACE and need reassessment and re-treatment planning
- Patients seeking downstaging therapy to become eligible for surgery or transplantation
- Patients interested in clinical trials of novel interventional and combination regimens
How CMCS Coordinates Your Care
China Medical Concierge Shanghai (CMCS) is a health management company — not a hospital. We connect international patients with Shanghai's leading interventional oncologists, including Dr. Shi Yaoping at Renji Hospital, and manage every step of the process:
- Review of existing liver imaging (MRI with hepatobiliary contrast, CT, ultrasound), AFP and other tumor markers, liver function tests, and prior treatment records
- Treatment planning consultation with Dr. Shi's team
- Coordination with hepatobiliary surgery, medical oncology, and liver transplant teams
- Appointment scheduling with priority access
- Medical interpretation during consultations and procedures
- Logistics support: accommodation near Renji Hospital, visa assistance, and local transport
- Post-procedure follow-up and remote monitoring coordination
Get in Touch
If you have liver cancer and are exploring comprehensive interventional treatment options in Shanghai, contact our team for a confidential consultation.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
댓글 0개